» Articles » PMID: 11808707

Serum Bilirubin and 10-year Mortality Risk in a Belgian Population

Overview
Specialties Oncology
Public Health
Date 2002 Jan 26
PMID 11808707
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The endogenous antioxidant serum bilirubin may scavenge free radicals and protect against free radical-related diseases.

Methods: Using the 10-year follow-up mortality data from the Belgium Inter-university Research on Nutrition and Health (BIRNH) study the association between serum bilirubin and all-cause, cardiovascular, and cancer mortality in 5460 men and 4843 women was investigated.

Results: In men, with the highest (> or = 0.6 mg/dl) compared with the lowest serum bilirubin concentration (< or = 0.2 mg/dl), the adjusted relative risk (RR) was 0.73 (95% confidence interval (CI) 0.57-0.94) for all-cause and 0.42 (95% Cl 0.26-0.68) for cancer mortality. The risk for cancer mortality decreased with increasing concentrations of serum bilirubin (p for trend = 0.004) especially for non-lung cancer mortality (p for trend = 0.02). The associations persisted after adjusting for smoking. In women the associations between serum bilirubin and cancer mortality were in the same direction, but did not reach statistical significance (RR = 0.76, 95% CI 0.39-1.5). No significant associations were found between serum bilirubin and cardiovascular mortality in men and women.

Conclusions: In this population high serum bilirubin, however, within normal ranges, was associated with low cancer mortality, especially in men. This may be due to the antioxidant activity of bilirubin. Measurement of serum bilirubin concentrations may contribute to cancer risk estimation.

Citing Articles

Predictive value of direct bilirubin and total bile acid in lung adenocarcinoma patients treated with EGFR-TKIs.

Li Y, Wang B, Fei S, Qin Y BMC Pulm Med. 2024; 24(1):583.

PMID: 39580432 PMC: 11585954. DOI: 10.1186/s12890-024-03367-1.


Novel prognostic score based on the preoperative total bilirubin-albumin ratio and fibrinogen-albumin ratio in ampullary adenocarcinoma.

Zhang X, Fei H, Sun C, Li Z, Li Z, Guo C World J Gastrointest Surg. 2023; 15(10):2247-2258.

PMID: 37969714 PMC: 10642462. DOI: 10.4240/wjgs.v15.i10.2247.


Toward nanotechnology-enabled application of bilirubin in the treatment and diagnosis of various civilization diseases.

Cui Y, Wu C, Li L, Shi H, Li C, Yin S Mater Today Bio. 2023; 20:100658.

PMID: 37214553 PMC: 10196858. DOI: 10.1016/j.mtbio.2023.100658.


Indirect bilirubin impairs invasion of osteosarcoma cells inhibiting the PI3K/AKT/MMP-2 signaling pathway by suppressing intracellular ROS.

Yuan X, Ma C, Li J, Li J, Yu R, Cai F J Bone Oncol. 2023; 39:100472.

PMID: 36876225 PMC: 9982672. DOI: 10.1016/j.jbo.2023.100472.


Blood ACE Phenotyping for Personalized Medicine: Revelation of Patients with Conformationally Altered ACE.

Danilov S, Jain M, Petukhov P, Kurilova O, Ilinsky V, Trakhtman P Biomedicines. 2023; 11(2).

PMID: 36831070 PMC: 9953529. DOI: 10.3390/biomedicines11020534.